The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.

The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

BioNTech will work with Scancell to discover and characterize T cell receptors and has an option to form a license agreement for the therapeutics.

The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and sees Sanofi obtain worldwide rights to fitusiran.

Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…